## Management of Clomiphene Citrate–Resistant PCOS **Key Point:** After failure of maximum tolerated clomiphene citrate (150 mg), the next step is to switch to exogenous gonadotropins (FSH) with low-dose step-up protocol and intensive ultrasound monitoring to minimize OHSS risk. ### Definition of CC Resistance - **Clomiphene citrate resistance** (or CC failure): Absence of ovulation despite 150 mg daily × 5 days for ≥3 consecutive cycles. - **Prevalence in PCOS**: 20–40% of women with PCOS do not respond to CC. - **Mechanism**: Insulin resistance, elevated LH (suppressing FSH action), and intrinsic ovarian dysfunction contribute to CC resistance. ### Why Gonadotropins Are Indicated Here 1. **Direct ovarian stimulation**: Exogenous FSH bypasses the HPO axis and directly stimulates follicle growth, overcoming the relative FSH deficiency in PCOS. 2. **Evidence-based**: ASRM and ESHRE guidelines recommend gonadotropins as second-line therapy after CC failure. 3. **Efficacy**: Ovulation achieved in 70–90% of CC-resistant PCOS patients. 4. **Monitoring**: Requires frequent ultrasound (every 2–3 days) and estradiol levels to prevent OHSS. ### Low-Dose Step-Up Protocol (Gold Standard in PCOS) ```mermaid flowchart TD A[CC-resistant PCOS<br/>FSH 75 IU daily]:::action --> B[Ultrasound day 7-8]:::decision B -->|No response| C[Increase by 37.5 IU<br/>every 7 days]:::action B -->|Follicle 12-14 mm| D[Continue same dose]:::action D --> E[Ultrasound day 10-12]:::decision E -->|Lead follicle ≥18 mm| F[hCG trigger 5000-10000 IU]:::action E -->|Follicle 14-17 mm| G[Repeat ultrasound<br/>in 2-3 days]:::action G --> F F --> H[Ovulation achieved]:::outcome C --> I[Ultrasound day 7 after increase]:::decision I -->|Response| D I -->|No response| C ``` **High-Yield:** Low-dose step-up (starting 75 IU, increments of 37.5 IU every 7 days) is preferred over high-dose fixed protocols because it reduces OHSS risk while maintaining ovulation rates. ### Comparison of Second-Line Options | Option | Mechanism | Efficacy in CC Resistance | OHSS Risk | Monitoring | Cost | |--------|-----------|--------------------------|-----------|------------|------| | **Exogenous FSH (low-dose step-up)** | Direct follicle stimulation | 70–90% | Low (with careful dosing) | Frequent ultrasound + E2 | Moderate | | **Letrozole** | Aromatase inhibitor; increases endogenous FSH | 40–50% in CC-resistant PCOS | Very low | Minimal | Low | | **Ovarian drilling** | Mechanical reduction of androgen-secreting stroma | 50–60% (variable) | None | None | High (surgical) | | **Increase CC dose** | Same mechanism as lower doses | <10% (already failed at 150 mg) | Low | Minimal | Very low | **Clinical Pearl:** Letrozole is an alternative second-line agent and may be tried before gonadotropins in some centers, especially if OHSS risk is a major concern. However, gonadotropins remain the gold standard in international guidelines for CC-resistant PCOS. **Warning:** Do NOT simply increase clomiphene citrate beyond 150 mg daily — doses >150 mg do not improve ovulation rates and increase adverse effects (visual disturbances, mood changes). Maximum recommended dose is 150 mg daily. ### Monitoring During Gonadotropin Therapy 1. **Baseline**: Pelvic ultrasound, serum estradiol. 2. **During stimulation**: Transvaginal ultrasound every 2–3 days; serum estradiol when follicles ≥14 mm. 3. **Trigger criteria**: Lead follicle ≥18 mm + 2–3 follicles ≥16 mm + estradiol <400 pg/mL (to minimize OHSS). 4. **Post-trigger**: Luteal phase support with progesterone if ovulation confirmed. **Mnemonic:** **PCOS-CC-Failure = FSH** — When clomiphene fails in polycystic ovary syndrome, switch to follicle-stimulating hormone (gonadotropins). [cite:ASRM Practice Committee Guidelines on Ovulation Induction in PCOS; Harrison 21e Ch 297]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.